{"title":"Analyzing Secondary Cancer Risk: A Machine Learning Approach.","authors":"Erfan Hatamabadi Farahani, Hossein Sadeghi, Fatemeh Seif, Mahdi Azad Marzabadi, Reza Rezaee","doi":"10.31557/APJCP.2025.26.1.239","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.</p><p><strong>Methods: </strong>Machine learning (ML) models have demonstrated their usefulness in forecasting the likelihood of SC risks based on effective doses in the organ. Linear regression analysis is a widely utilized technique for examining the relationship between predictor variables and continuous responses, particularly in scenarios with limited sample sizes. This study employs linear regression models to analyze the relationship between effective dose and the risk of SC, comparing different prediction methods across lung, colon, and breast cancer.</p><p><strong>Result: </strong>The results indicate that the risk of SC increases with the effective dose in the organ. The linear regression model provides coefficients that mirror the radiation sensitivity of the specific organ, demonstrating the model's effectiveness in predicting SC risk based on dose.</p><p><strong>Conclusion: </strong>The study highlights the significance of using linear regression models to predict the risk of SC based on effective doses in the organ. The findings underscore the importance of considering the radiation sensitivity of specific organs in SC risk prediction, which can aid in better understanding and managing the long-term health of cancer survivors.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 1","pages":"239-248"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.1.239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.
Methods: Machine learning (ML) models have demonstrated their usefulness in forecasting the likelihood of SC risks based on effective doses in the organ. Linear regression analysis is a widely utilized technique for examining the relationship between predictor variables and continuous responses, particularly in scenarios with limited sample sizes. This study employs linear regression models to analyze the relationship between effective dose and the risk of SC, comparing different prediction methods across lung, colon, and breast cancer.
Result: The results indicate that the risk of SC increases with the effective dose in the organ. The linear regression model provides coefficients that mirror the radiation sensitivity of the specific organ, demonstrating the model's effectiveness in predicting SC risk based on dose.
Conclusion: The study highlights the significance of using linear regression models to predict the risk of SC based on effective doses in the organ. The findings underscore the importance of considering the radiation sensitivity of specific organs in SC risk prediction, which can aid in better understanding and managing the long-term health of cancer survivors.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.